103 related articles for article (PubMed ID: 21470580)
1. The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination.
Parvanova I; Rettig L; Knuth A; Pascolo S
Vaccine; 2011 May; 29(22):3832-6. PubMed ID: 21470580
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
3. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
5. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
7. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
9. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
10. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
11. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
13. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
Li Y; Subjeck J; Yang G; Repasky E; Wang XY
Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072
[TBL] [Abstract][Full Text] [Related]
14. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
15. Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm.
Kitamura H; Sedlik C; Jacquet A; Zaragoza B; Dusseaux M; Premel V; Sastre-Garau X; Lantz O
J Immunol; 2010 Jul; 185(2):892-901. PubMed ID: 20543102
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
19. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
